AIP
VYGR icon

Almanack Investment Partners’s Voyager Therapeutics VYGR Stock Holding History

Almanack Investment Partners’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.3K Buy
+11,500
New +$43.6K 0.01% 316

Other funds holding VYGR

EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
PFGIA
Patriot Financial Group Insurance Agency Westborough, Massachusetts $974M AUM 29.77% 1-Year Est. Return
HPCM
Hunter Perkins Capital Management Lombard, Illinois $446M AUM 25.88% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
EI
Ethic Inc New York $8.02B AUM 45.39% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Almanack Investment Partners's VYGR Position: Q2 2026 in Review

Almanack Investment Partners opened a new position in Voyager Therapeutics (VYGR) in Q2 2026: 11,500 shares worth $40.3K. The stake represents 0.01% of the portfolio and ranks #316 among its holdings.

27 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.

  • Almanack Investment Partners held 11,500 shares of Voyager Therapeutics worth $40.3K as of Q2 2026.
  • Voyager Therapeutics was a new Almanack Investment Partners position in Q2 2026.
  • Voyager Therapeutics made up 0.01% of Almanack Investment Partners's portfolio in Q2 2026, its #316 holding.
  • 27 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.

Based on Almanack Investment Partners's 13F filing for Q2 2026, filed 30 Jul 2026.